Insight Molecular Diagnostics Inc. Common Stock (IMDX)

Price$3.99

Favorite Metrics

Price vs S&P 500 (26W)-10.03%

Price vs S&P 500 (4W)-19.35%

Market Capitalization$128.35M

All Metrics

Book Value / Share (Quarterly)$0.04

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)61.65%

Cash Flow / Share (Quarterly)$-0.88

Price vs S&P 500 (YTD)-52.94%

Gross Margin (TTM)56.97%

Net Profit Margin (TTM)-1238.52%

EPS (TTM)$-1.62

10-Day Avg Trading Volume0.41M

EPS Excl Extra (TTM)$-1.62

Revenue Growth (5Y)27.15%

EPS (Annual)$-1.65

ROI (Annual)-108.54%

Gross Margin (Annual)56.67%

Net Profit Margin (5Y Avg)-3363.86%

Cash / Share (Quarterly)$0.40

Revenue Growth QoQ (YoY)-23.35%

ROA (Last FY)-194.99%

Revenue Growth TTM (YoY)115.58%

EBITD / Share (TTM)$-1.57

ROE (5Y Avg)-110.62%

Operating Margin (TTM)-1260.76%

Cash Flow / Share (Annual)$-0.88

P/B Ratio116.89x

P/B Ratio (Quarterly)787.10x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)29.06x

Net Interest Coverage (TTM)-459.75x

ROA (TTM)-111.25%

EPS Incl Extra (Annual)$-1.65

Current Ratio (Annual)1.27x

Quick Ratio (Quarterly)1.11x

3-Month Avg Trading Volume0.13M

52-Week Price Return35.69%

Revenue / Employee (TTM)$0

P/S Ratio (Annual)31.65x

Asset Turnover (Annual)0.16x

52-Week High$8.51

Operating Margin (5Y Avg)-2088.66%

EPS Excl Extra (Annual)$-1.65

CapEx CAGR (5Y)20.96%

26-Week Price Return-1.29%

Quick Ratio (Annual)1.11x

13-Week Price Return-43.94%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.27x

Enterprise Value$117.827

Revenue / Share Growth (5Y)-18.63%

Asset Turnover (TTM)0.09x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1238.52%

Cash / Share (Annual)$0.40

3-Month Return Std Dev130.79%

Gross Margin (5Y Avg)37.19%

Net Income / Employee (TTM)$-1

ROE (Last FY)-108.54%

Net Interest Coverage (Annual)-459.75x

EPS Basic Excl Extra (Annual)$-1.65

Receivables Turnover (TTM)2.96x

Total Debt / Equity (Quarterly)0.92x

EPS Incl Extra (TTM)$-1.62

Receivables Turnover (Annual)2.96x

ROI (TTM)-374.15%

P/S Ratio (TTM)31.65x

Pretax Margin (5Y Avg)-2091.79%

Revenue / Share (Annual)$0.13

Price vs S&P 500 (52W)0.59%

Year-to-Date Return-48.80%

5-Day Price Return28.00%

EPS Normalized (Annual)$-1.65

ROA (5Y Avg)-103.60%

Net Profit Margin (Annual)-1238.52%

Month-to-Date Return17.07%

EBITD / Share (Annual)$-1.56

Operating Margin (Annual)-1260.76%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-106.68%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.62

Inventory Turnover (TTM)4.08x

Pretax Margin (TTM)-1238.52%

Price vs S&P 500 (13W)-46.81%

Beta1.60x

Revenue / Share (TTM)$0.13

ROE (TTM)-426.68%

52-Week Low$2.33

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

3.90

Industry Peers — In Vitro Diagnostics(17)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IMDXInsight Molecular Diagnostics Inc. Common Stock	31.65x	115.58%	56.97%	—	$3.99
IDXXIdexx Laboratories Inc	10.72x	10.42%	61.80%	14.28%	$583.06
LNTHLantheus Holdings, Inc	3.55x	0.50%	61.10%	40.71%	$83.97
NNNNAnbio Biotechnology Class A Ordinary Shares	295.25x	-5.72%	89.00%	—	$26.98
CLDXCelldex Therapeutics, Inc	1753.49x	-77.98%	17.65%	—	$34.38
NEOGNeogen Corp	2.39x	-3.91%	45.20%	—	$9.63
NTLAIntellia Therapeutics, Inc	26.55x	16.92%	—	—	$15.21
QDELQuidelOrtho Corporation Common Stock	0.32x	-1.89%	46.67%	—	$12.89
MYGNMyriad Genetics Inc	0.59x	-1.56%	69.93%	—	$5.14
ACHVAchieve Life Sciences, Inc.	12.70x	-89.25%	—	—	$4.25
TKNOAlpha Teknova, Inc. Common Stock	3.87x	7.35%	33.17%	—	$2.91

About

Insight Molecular Diagnostics is a molecular diagnostics company that uses donor-derived cell-free DNA (dd-cfDNA) quantification technology for transplant monitoring and related applications. The company markets GraftAssureIQ, a research-use-only test kit, and is developing GraftAssureDx, a clinical-grade product for broader adoption. Its mission is to democratize access to advanced molecular diagnostic testing to improve patient outcomes.